|
Clinical cure
|
Clinical failure
|
P value
|
---|
All patients (n = 249)
|
n = 229
|
n = 20
| |
At presentation
|
PCT
|
0.40 (0.13–1.54)
|
0.36 (0.10–1.46)
|
0.749
|
PCT > 0.25
|
136 (59%)
|
12 (60%)
|
0.957
|
CRP
|
120 (53–211)
|
90 (27–223)
|
0.851
|
proADM
|
0.89 (0.62–1.30)
|
0.86 (0.67–1.20)
|
0.948
|
Day 3
|
PCT
|
0.18 (0.07–0.87)
|
0.12 (0.04–0.69)
|
0.667
|
PCT ≤ 0.25
|
122 (60%)
|
12 (67%)
|
0.568
|
PCT ≤ 0.25 or PCT decline ≥80%
|
144 (71%)
|
14 (78%)
|
0.519
|
proADM
|
0.66 (0.50–0.91)
|
0.63 (0.51–0.78)
|
0.667
|
Short treatment (n = 92)
|
n = 82
|
n = 10
| |
At presentation
|
PCT
|
0.34 (0.10–1.68)
|
0.36 (0.11–1.79)
|
0.980
|
PCT > 0.25
|
47 (57%)
|
6 (60%)
|
0.871
|
CRP
|
123 (53–194)
|
77 (15–142)
|
0.231
|
proADM
|
0.76 (0.56–1.04)
|
0.85 (65–1.25)
|
0.360
|
Day 3
|
PCT
|
0.12 (0.06–0.42)
|
0.13 (0.09–0.63)
|
0.794
|
PCT ≤ 0.25
|
51 (66%)
|
7 (78%)
|
0.484
|
PCT ≤ 0.25 or PCT decline ≥80%
|
62 (80%)
|
8 (89%)
|
0.542
|
proADM
|
0.56 (0.47–0.76)
|
0.59 (0.53–0.74)
|
0.679
|
Long treatment (n = 157)
|
n = 147
|
n = 10
| |
At presentation
|
PCT
|
0.48 (0.15–1.49)
|
0.48 (0.09–3.13)
|
0.826
|
PCT > 0.25
|
89 (60%)
|
6 (60%)
|
0.973
|
CRP
|
119 (52–224)
|
181 (37–263)
|
0.531
|
proADM
|
0.98 (0.67–1.44)
|
0.86 (0.62–1.21)
|
0.495
|
Day 3
|
PCT
|
0.22 (0.08–1.08)
|
0.08 (0.04–0.72)
|
0.358
|
PCT ≤ 0.25
|
71 (56%)
|
5 (56%)
|
0.984
|
PCT ≤ 0.25 or PCT decline ≥80%
|
82 (65%)
|
6 (67%)
|
0.899
|
proADM
|
0.74 (0.53–1.03)
|
0.74 (0.47–1.02)
|
0.609
|
- Data presented as median (IQR) or number (%)
- CRP at presentation missing: n = 41 in short treatment and n = 41 in long treatment